Monitoring patient safety during clinical trials is a critical component throughout the drug development life-cycle. Pharmaceutical sponsors must work proactively and collaboratively with all stakeholders to ensure a systematic approach to safety monitoring. The regulatory landscape has evolved with increased requirements for risk management plans, risk evaluation and minimization strategies. As the industry transitions from passive to active safety surveillance activities, there will be greater demand for more comprehensive and innovative approaches that apply quantitative methods to accumulating data from all sources, ranging from the discovery and preclinical through clinical and post-approval stages. Statistical methods, especially those based on the Bayesian framework, are important tools to help provide objectivity and rigor to the safety monitoring process.
References
[1]
International Conference on Harmonization (ICH). Guideline for Good Clinical Practice E6(R1), 1996. Available online: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6_R1/Step4/E6_R1__Guideline.pdf (accessed on 8 October 2010).
[2]
Council for International Organizations of Medical Sciences (CIOMS) in collaboration with the World Health Organization (WHO). International Ethical Guidelines for Biomedical Research Involving Human Subjects. CIOMS & WHO: Geneva, Switzerland, 2002.
[3]
The Declaration of Helsinki; World Medical Association: Somerset West, South Africa, 1996.
[4]
European Clinical Trials Directive 2001/20/EC. Available online: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2001:121:0034:0044:en:PDF (accessed on 09 October 2012).
[5]
United States Food and Drug Administration. Guidance for Industry, Premarketing Risk Assessment, 2005. Available online: http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm126958.pdf (accessed on 09 October 2012).
[6]
Food and Drug Administration (FDA). Guidance for Industry, Development and Use of Risk Minimization Action Plans, 2005. Available online: http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM126830.pdf (accessed on 09 October 2012).
[7]
Food and Drug Administration (FDA). Guidance for Industry, Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment, 2005. Available online: http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM126834.pdf (accessed on 09 October 2012).
[8]
Grady, C. Payment of Clinical Research Subjects. J. Clin. Invest. 2005, 115, 1681–1687, doi:10.1172/JCI25694.
[9]
Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Guidance for industry and investigators: Safety reporting requirements for INDs and BA/BE studies, 2010. Available online: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM227351.pdf (accessed on 09 October 2012).
[10]
Council for International Organizations of Medical Sciences (CIOMS) Working Group VI. Management of safety information from clinical trials. CIOMS: Geneva, Switzerland, 2005.
[11]
Crowe, B.J.; Xia, H.A.; Berlin, J.A.; Watson, D.J.; Shi, H.; Lin, S.L.; Kuebler, J.; Schriver, R.C.; Santanello, N.C.; Rochester, G.; et al. Recommendations for safety planning, data collection, evaluation and reporting during drug, biologic and vaccine development: A report of the safety planning, evaluation andreporting team. Clin. Trials 2009, 6, 430–440.
[12]
Xia, H.A.; Crowe, B.J.; Schriver, R.C.; Oster, M.; Hall, D.B. Planning and core analyses for periodic aggregate safety data reviews. Clin. Trials 2011, 8, 175–182, doi:10.1177/1740774510395635.
[13]
Wald, A. Sequential tests of statistical hypotheses. Ann. Math. Stat. 1945, 16, 117–186, doi:10.1214/aoms/1177731118.
[14]
Wald, A. Sequential Analysis; Wiley: New York, NY, USA, 1947.
[15]
Goldman, A.; Hannan, P. Optimal continuous sequential boundaries for monitoring toxicity in clinical trials: A restricted search algorithm. Stat. Med. 2001, 20, 1575–1589, doi:10.1002/sim.713.
[16]
Thall, C.P.; Simon, R. Practical Bayesian guidelines for phase IIB clinical trials. Biometrics 1994, 50, 337–349, doi:10.2307/2533377.
[17]
Yin, G. Clinical Trial Design: Bayesian and Frequentist Adaptive Methods. Wiley: Hoboken, NJ, USA, 2012.
[18]
Ball, G. Continuous safety monitoring for randomized controlled clinical trials with blinded treatment information. Contemp. Clin. Trials 2011, 32, S11–S17, doi:10.1016/j.cct.2011.05.008.
[19]
SISA. Wald’s Sequential Probability. Available online: http://www.quantitativeskills.com/sisa/statistics/sprt.htm (accessed on 09 October 2012).
[20]
MD Anderson Cancer Center, Software Download Site, Multc Lean. Available online: https://biostatistics.mdanderson.org/SoftwareDownload (accessed on 09 October 2012).
